Opthea Limited
OPT.ASXHealth Care
Opthea is a drug development company developing innovative, biologics-based therapies for the treatment of eye disease.
Latest Earnings
Appendix 4D and Half Year Report for period 31 Dec 2025
2 March 2026
Opthea pivoted to a rare disease focus, completing a strategic review and terminating its Development Funding Agreement (DFA), resulting in a $339.9M profit swing. The $357.1M gain from DFA derecognition masked underlying operating losses of $7.1M as the company streamlined operations by 80% and repositioned to develop OPT-302 for Lymphangioleiomyomatosis (LAM), a rare lung disease, with $33.2M cash on hand and no near-term capital raise required. Key points: DFA settlement eliminates $377M liability, generating $357.1M accounting gain and resolving major balance sheet constraint; Strategic repositioning to LAM (rare lung disease) leverages existing OPT-302 asset with strong scientific rationale and unmet medical need; Dramatic cost reduction: 80% workforce cut, R&D expenses fell 99% to $1.3M; $10.8M R&D tax credit received in October 2025
Recent Announcements
Becoming a substantial holder
Jagen Nominees Pty Ltd and its relevant entities became a substantial holder in Opthea Limited (ASX: OPT) on 23 June 2026, acquiring 132,307,713 ordinary shares representing 9.66% voting power in the company.
Ceasing to be a substantial holder
JAF CAPITAL PTY LTD ceased to be a substantial holder.
Ceasing to be a substantial holder
Regal Partners Funds Management Pty Limited and its associates ceased to be a substantial holder.
Ceasing to be a substantial holder
The Bank of New York Mellon Corporation (BNY) ceased to be a substantial holder.
Becoming a substantial holder
JAF CAPITAL PTY LTD became a substantial holder (5.04%).
Notice of Market Update
Opthea Limited (ASX:OPT) will host an online webinar on Friday 12 June 2026 at 11:00am AEST, where Executive Chair Jeremy Levin will provide a corporate update to analysts and investors.
Appendix 4D and Half Year Report for period 31 Dec 2025
Opthea pivoted to a rare disease focus, completing a strategic review and terminating its Development Funding Agreement (DFA), resulting in a $339.9M profit swing. The $357.1M gain from DFA derecognition masked underlying operating losses of $7.1M as the company streamlined operations by 80% and repositioned to develop OPT-302 for Lymphangioleiomyomatosis (LAM), a rare lung disease, with $33.2M cash on hand and no near-term capital raise required. Key points: DFA settlement eliminates $377M liability, generating $357.1M accounting gain and resolving major balance sheet constraint; Strategic repositioning to LAM (rare lung disease) leverages existing OPT-302 asset with strong scientific rationale and unmet medical need; Dramatic cost reduction: 80% workforce cut, R&D expenses fell 99% to $1.3M; $10.8M R&D tax credit received in October 2025
Get real-time alerts for OPT
Receive AI-powered earnings summaries and instant notifications when Opthea Limited releases results.
Register Free